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Abstract
Introduction: Intensive care unit mortality is strongly associated with organ failure rate and severity. The sequential
organ failure assessment (SOFA) score is used to evaluate the impact of a successful tight glycemic control (TGC)
intervention (SPRINT) on organ failure, morbidity, and thus mortality.
Methods: A retrospective analysis of 371 patients (3,356 days) on SPRINT (August 2005 - April 2007) and 413
retrospective patients (3,211 days) from two years prior, matched by Acute Physiology and Chronic Health
Evaluation (APACHE) III. SOFA is calculated daily for each patient. The effect of the SPRINT TGC intervention is
assessed by comparing the percentage of patients with SOFA ≤5 each day and its trends over time and cohort/
group. Organ-failure free days (all SOFA components ≤2) and number of organ failures (SOFA components >2) are
also compared. Cumulative time in 4.0 to 7.0 mmol/L band (cTIB) was evaluated daily to link tightness and
consistency of TGC (cTIB ≥0.5) to SOFA ≤5 using conditional and joint probabilities.
Results: Admission and maximum SOFA scores were similar (P = 0.20; P = 0.76), with similar time to maximum
(median: one day; IQR: [1,3] days; P = 0.99). Median length of stay was similar (4.1 days SPRINT and 3.8 days Pre-
SPRINT; P = 0.94). The percentage of patients with SOFA ≤5 is different over the first 14 days (P = 0.016), rising to
approximately 75% for Pre-SPRINT and approximately 85% for SPRINT, with clear separation after two days. Organ-
failure-free days were different (SPRINT = 41.6%; Pre-SPRINT = 36.5%; P < 0.0001) as were the percent of total
possible organ failures (SPRINT = 16.0%; Pre-SPRINT = 19.0%; P < 0.0001). By Day 3 over 90% of SPRINT patients
had cTIB ≥0.5 (37% Pre-SPRINT) reaching 100% by Day 7 (50% Pre-SPRINT). Conditional and joint probabilities
indicate tighter, more consistent TGC under SPRINT (cTIB ≥0.5) increased the likelihood SOFA ≤5.
Conclusions: SPRINT TGC resolved organ failure faster, and for more patients, from similar admission and
maximum SOFA scores, than conventional control. These reductions mirror the reduced mortality with SPRINT. The
cTIB ≥0.5 metric provides a first benchmark linking TGC quality to organ failure. These results support other
physiological and clinical results indicating the role tight, consistent TGC can play in reducing organ failure,
morbidity and mortality, and should be validated on data from randomised trials.
Introduction
After the first two to three days of patient stay, mortal-
ity in the intensive care unit (ICU) and in-hospital are
strongly associated with, and/or attributable to, organ
failure and sepsis [1-3]. In particular, a lack of organ
failure resolution over a patient’s stay is associated with
increased morbidity and mortality, as commonly mea-
sured by the sequential organ failure assessment (SOFA)
score [4-6]. However, the specific mechanisms are not
necessarily fully understood [7-10].
Blood glucose levels and their variability have also
been associated with increased organ failure, morbidity
and mortality, particularly in sepsis [11-14]. Hyperglyce-
mia can have lasting impact at a cellular level, even in
subsequent euglycemia, due to over production of
superoxides [15], leading to further damage and compli-
cations. Hyperglycemia can also increase pro-inflamma-
tory nitric oxide synthase activity, as part of the process
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with reduced microvascular circulation, and reduced
organ perfusion, all of which can be potentially reversed
with insulin [16,17]. Tight glycemic control (TGC) by
intensive insulin therapy (IIT) has been successful at
reducing mortality and/or organ failure in some prior
studies [18-21]. There are also strong physiological links
between reduced glycemic levels (and reduction in their
variability), and improved immune response to infection
[22-24] as well as reductions in organ failure [8]. It is
particularly interesting to note that while mortality was
reduced for patients with length of stay three days or
longer, differences in Kaplan-Meier plots do not appear
before 10 to 15 days for these studies. These results sug-
gest that earlier resolution of organ failure and dysfunc-
tion, and the resulting reduced morbidity, is a leading
cause of at least part of the improvement. Additionally,
while some studies showed benefit from TGC, several
others have not achieved similar results [25-27], and
equally, did not necessarily achieve (where reported) the
same affect in mitigating organ failure.
Hence, this study hypothesises that TGC can mitigate
organ failure and severity more rapidly in the first days
of intensive care as a platform for improved outcome.
To test this hypothesis, the data from the retrospective
SPRINT glycemic control study [21] was revisited and
SOFA scores calculated for all 784 patients considered
in the study (371 on SPRINT and 413 retrospective
matched patients) for each day of ICU stay. Organ fail-
ure was calculated daily using the SOFA score for each
patient. This study analyses these SOFA score trajec-
tories to determine if organ failure was mitigated more
rapidly in our TGC cohort, indicating a potential reason
for the improved mortality that appears later in the stay.
Further analyses examine differences in survivors and
non-survivors, as well as the number of organ failures
and organ failure free days in each cohort.
Materials and methods
SPRINT protocol
SPRINT is a model-derived [28,29] TGC protocol devel-
oped from clinically validated computer models used for
real-time control in the ICU [28-32]. Implemented at
the Christchurch Hospital Department of Intensive Care
in August 2005 [21], SPRINT has now been used on
over 1,000 patients. In a clinical comparison to statisti-
cally matched retrospective cohorts, the SPRINT TGC
intervention reduced hospital mortality for those
patients staying three to five days in the ICU by 25 to
40% [21].
SPRINT is a unique TGC protocol that uses explicit
control of both insulin and nutrition inputs. It thus con-
trols carbohydrate intake in balance with the insulin
given, which is the unique feature of this protocol
compared to all others. Other TGC protocols leave car-
bohydrate intake to local standards and do not explicitly
account for its intake, delivery route or total dose in try-
ing to achieve glycemic control [33-35]. In particular,
SPRINT modulates nutritional intake between 30 to
100% of a patient-specific goal feed rate based on
ACCP/SCCM guidelines [36]. SPRINT also specifies
only low-carbohydrate enteral nutrition formulas with
35 to 40% carbohydrate content, unless clinically speci-
fied otherwise in rare cases. SPRINT is thus primarily
unique in explicitly specifying and using carbohydrate
intake, within acceptable ranges [36-38] for TGC.
Equally importantly, SPRINT determines insulin and
nutrition interventions based on (estimated) insulin sen-
sitivity of the patient (1/insulin resistance), rather than
strictly on blood glucose levels or/and changes. Hence,
insulin and nutrition are given in balance, based on esti-
mated response to the prior insulin and nutrition inter-
vention, which is enabled by the protocols explicit
knowledge of carbohydrate intake. The overall system
thus matches the nutrition and exogenous insulin given
to the body’s patient-specific ability to utilise them, thus
avoiding hyperglycemia. This approach is unique to
SPRINT.
SPRINT also modulates interventions very slowly.
Over 90% of interventions change insulin or nutrition
rates by ± 1 U/hour and/or ± 10% (nutrition rate), or
less. Further, large drops in blood glucose (>1.5 mmol/
L with BG <7 mmo/L) trigger the shut off of insulin
even though blood glucose is over the 6.0 mmol/L tar-
get. This relatively slow, very conservative approach is
much less aggressive than almost all other protocols,
minimising rapid changes in glycemia and thus
hypoglycemia.
Finally, SPRINT measures more frequently than
almost all other protocols. It specifies one or two hourly
measurement and intervention intervals. This rate is
also based on patient-specific insulin sensitivity. This
feature is also unique compared to other protocols that
typically utilise reaching a glycemic band or similar gly-
cemic outcome to change measurement frequency.
More specifically, it requires a patient to be stable
which is defined as in the target band (4 to 6 mmol/L,
target of 6 mmol/L) for three hours with higher than
average insulin sensitivity (low insulin resistance), as
assessed by receiving 3 U/hour or less of insulin and
60% or more goal nutrition rate. Hence, stability, and
thus measurement frequency are a function of a
patient’s assessed insulin sensitivity as a broad marker of
their level of wellness and potential variability. Equally,
the protocol does not allow a four-hour measurement,
as many others do, which ensures that glycemic control
is not lost for patients who can demonstrate significant
hourly metabolic variability [28,39,40].
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particular, it reported very high times in tight glycemic
bands compared to other studies [41]. SPRINT also pro-
vided tight control more consistently across patients
where the median blood glucose for the 25
th and 75
th
percentile patients was separated by 1.1 mmol/L (1.9
mmol/L for the 5
th and 95
th percentiles). Overall, 97%
of patients had 50% or more of their glucose values
within a 4.0 to 7.0 mmol/L range. More importantly,
while SPRINT gave more insulin it is the only reported
study that reduced hypoglycemia (<2.2 mmol/L) in the
tight control group (2% by patient a 50% reduction from
Pre-SPRINT). It also had a lower carbohydrate load
than Pre-SPRINT due the nutrition specified and its for-
mulation. Finally, and perhaps most importantly, there
was no statistical association within the SPRINT cohort
between mortality and any glycemic metric (median,
average, range, maximum), indicating that all patients
received equal (tight) control, and that glycemia was no
longer a significant factor in mortality, which was not
t h ec a s ef o rt h er e t r o s p e c t i v ec o h o r t .A p p e n d i xAi n
Additional File 1 contains a more detailed description of
SPRINT and specific, unique differences to other proto-
cols and Table 1 has a selection of glycemic and inter-
vention results from the study.
Pre-SPRINT glycemic control consisted of a standard
glucose sliding scale for which aggressiveness could be
adjusted [28]. Measurement frequency was not specified,
but was approximately every four hours across the
cohort (Table 1). As seen in Table 1 it still provided
relatively good glycemic control compared to some stu-
dies with an average value of 7.2 mmol/L. However, this
may be misleading as results were highly variable across
patients.
Table 1 Comparison of SPRINT and retrospective cohort baseline variables with glycemic control and intervention
results
Overall
Retrospective SPRINT P-value
Total patients 413 371
Age (years) 64 (53 to 74) 65 (49 to 74) 0.53
% Male 59.1% 63.6% 0.19
APACHE II score 18 (15 to 23) 18 (15 to 24) 0.50
APACHE II risk of death 28.5% (14.2% to 49.7%) 25.7% (13.1% to 49.4%) 0.39
Diabetic history 71 (17.2%) 62 (16.7%) 0.86
LoS median, IQR (days) 3.8 (1.8 to 8.8) 4.1 (1.7 to 10.4) 0.94
Median BG (SD) (mmol/L) 7.2 (2.4) 6.0 (1.5) <0.01
% BG in 4.4-6.1 mmol/L 30.0% 53.9% <0.01
% BG in 4.0-7.0 mmol/L 49.6% 80.1% <0.01
% BG < 2.2 mmol/L 0.2% 0.1% <0.01
Mean insulin rate (U/hour) 1.2 2.8 <0.01
Mean nutrition (kcal/day) 1,599 1,283 <0.01
APACHE III diagnosis
Operative Num. patients % Num. patients % P-value
Cardiovascular 99 24% 76 20% 0.24
Respiratory 10 2% 9 2% 1.00
Gastrointestinal 53 13% 60 16% 0.18
Neurological 9 2% 7 2% 0.77
Trauma 8 2% 14 4% 0.12
Other (Renal, metabolic, orthopaedic) 4 1% 4 1% 0.88
Non-operative Num. patients % Num. patients % P-value
Cardiovascular 41 10% 39 11% 0.79
Respiratory 77 19% 66 18% 0.76
Gastrointestinal 7 2% 10 3% 0.34
Neurological 33 8% 20 5% 0.15
Trauma 29 7% 32 9% 0.40
Sepsis 29 7% 17 5% 0.15
Other (Renal, metabolic, orthopaedic) 14 3% 17 5% 0.39
P-values computed using chi-squared and rank-sum tests where appropriate.
APACHE, Acute Physiology and Chronic Health Evaluation; BG, blood glucose (level); IQR, inter-quartile range; LoS, length of stay; SD, standard deviation.
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This study uses data from 371 patients treated on
SPRINT (August 2005 to May 2007) and 413 patients
from (January 2003 to August 2005) prior to SPRINT,
as in the original study [21]. Patients were selected on a
per-protocol basis, based on matching initial blood glu-
cose levels criteria and being given insulin therapy. They
were similar in age, sex, and APACHE III diagnosis,
including a randomised analysis to ensure robustness.
Table 1 shows the overall patient data for both groups,
as well as a selection of glycemic and intervention
results from the original study. Further details on the
selection and analysis of these cohorts is in [21]. The
Upper South Regional Ethics Committee New Zealand
granted ethics approval for the audit, analysis and publi-
cation of this data.
Organ failure assessment
Hospital records were examined for all patients and
each day of their ICU stay. The total SOFA score
[4,5,42] was calculated daily for each patient, taking the
most abnormal value for each parameter in each 24 hr
period of ICU stay. Where a data point was missing or
not available for a component, a value was interpolated
from surrounding data. In this study, the Glasgow Coma
score reflecting central nervous system function was
excluded due to its reported lack of robustness and
unreliability [43-47], and it is thus not consistently
recorded in Christchurch Hospital. Other studies have
made a similar exclusion [48]. The remaining five SOFA
component scores are each directly related to organ
function or failure, and thus yield a maximum score of
20 (0 to 4 per metric). The parameters used assess
renal, cardiovascular, liver, and respiratory function, and
blood coagulation. A high SOFA score indicates a high
level of organ dysfunction.
Analysis and statistics
The primary goal is to retrospectively examine the
impact of TGC in mitigating organ failure using the
SOFA score. Thus, each cohort is evaluated in terms of
the number of patients with total SOFA score less than
5 each day (scores of 0 to 1 per category on average).
This value represents a low level of dysfunction. A lit-
erature survey shows that this cut-off value is well
below mean or median reported values for admission or
long-term average scores in several studies and is thus
indicative of relatively well patients [5,27,42,49-52].
Further, some studies show that a value of 5 or less
includes only the lowest scoring (least organ failure) 10
to 25% of patients, even when accounting for the miss-
ing central nervous system criterion in this study [5,52].
A further study used a cut-off of 7 as relatively well
[50]. Hence, the cut-off value of 5 appears to represent
a reasonable, potentially conservative, value to represent
a relatively well patient with resolving organ failure,
reduced morbidity and thus an increased likelihood of
survival.
Data are also presented for each cohort in terms of
total SOFA score and its variation over ICU days. Dif-
ferences between survivors and non-survivors are also
examined. The results for specific organ failure scores
(SOFA component scores) are examined for any notable
differences over time. Finally, organ failure free days
(OFFD) are considered, defined as a day in which a
patient has no SOFA component score greater than 2,
w h e r eaS O F Ac o m p o n e n tv a l u eo f3o r4i n d i c a t e sa
failure of that particular organ system, as defined in
other literature [3,5,48]. These latter results are thus
also considered in terms of individual organ (compo-
nent) failures (IOF). IOF counts the percentage of indi-
vidual SOFA score components of 3 or 4 (failure) out of
the maximum total possible organ failures (where Max
= 5 components × total patient days). Thus, OFFD is a
surrogate for the speed of resolution and/or prevention
of organ failure in the cohort, while IOF is a comple-
mentary cohort-wide measure of total organ failures.
To delineate the particular patients affected and for
which SOFA scores the greatest changes were seen over
time, SOFA score distributions for each day are also
presented. For conciseness and clarity, curves of mean
SOFA score are shown over the first 14 days of ICU
stay for each cohort. To illustrate any differences in the
more critically ill patients with SOFA ≥5o rm u c h
higher, the mean plus one standard deviation line or
83
rd percentile is also shown. These figures thus indicate
how TGC affects SOFA scores for more critically ill
patients, rather than just the trend for the mean patient.
Where required, SOFA score data over time are com-
pared using the non-parametric Wilcoxon sign-rank
test. The non-parametric Wilcoxon rank-sum test is
used to compare data distributions. The Fisher exact
test is used to compare OFFD, IOF and SOFA mortality
data. A statistical test value of P <0.05 is considered
significant in all cases.
Relating TGC and SOFA score
A patient-specific daily metric of control quality is
needed to assess any link between effective TGC and
SOFA outcome. For this analysis, cumulative Time in
Band (cTIB) is defined as the percentage of time a
patient’s blood glucose has been in a specified band
(cumulatively) up to that point in time. Good control
was defined based on the 95
th percentile patient
response in SPRINT as cTIB >0.50 (50%) within a 4.0 to
7.0 mmol/L band. Over 90% of SPRINT patients reach
this level by Day 3, so this definition captures the
SPRINT cohorts’ glycemic control. Cumulative time in
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sistent, safe, and tight (to target and not variable) TGC
under SPRINT that provided the foundation for
improved organ failure.
Specifically, cTIB was determined each day for each
patient, creating a data pair of (cTIB, SOFA) for each
day. Thus, patients can be separated into good (cTIB
≥0.5) or poor (cTIB <0.5) control, and SOFA ≤5o r
SOFA >5. To test the link between TGC and SOFA
score we developed the conditional probability of SOFA
≤5 given good control (cTIB ≥0.5) or P(SOFA ≤5 | cTIB
≥0 . 5 ) .T h e s ep r o b a b i l i t i e sa r eo u to f1 . 0 ,s h o w i n gt h e
association of good control with SOFA ≤5f o rag i v e n
day. This value is plotted for each day and cohort along
with the percent of total patients who achieve good
control.
In addition, the joint probability of each group is also
assessed. These joint probabilities cover all four combina-
tions of cTIB AND SOFA score for each day, and thus
sum to 1.0 across all four for a given day and cohort.
These probabilities are defined in Equations 1 to 4:
P SOFA 5 cTIB 5 joint probability of SOFA 5 and cTIB ≤∩ ≥ () =≤ ≥ 00 . .5 5 (1)
Where this joint probability is calculated for each day
out of all patients in each cohort, showing those patients
with low SOFA scores and good control.
P SOFA 5 cTIB 5 joint probability of SOFA 5 and cTIB ≤∩ < () =≤ < 00 . .5 5 (2)
Where this joint probability is calculated for each day
out of all patients in each cohort, showing those patients
who had low SOFA scores despite poor control.
The joint probabilities in Equations 1 to 2 cover those
patients who have low SOFA scores. Similarly for those
who do not have low SOFA scores:
P SOFA 5 cTIB 5 joint probability of SOFA 5 and cTIB >∩ ≥ () => ≥ 00 . .5 5 (3)
Where this joint probability is calculated for each day
out of all patients in each cohort, showing those patients
with higher SOFA scores, despite good control.
P SOFA 5 cTIB 5 joint probability of SOFA 5 and cTIB >∩ < () => < 00 . .5 5 (4)
Where this joint probability is calculated for each day
out of all patients in each cohort, showing those patients
who had higher SOFA scores and poor control.
These four cases in Equations 1 to 4 define this
paper’s hypothesis of good control and reduced SOFA
scores, but also show the other cases in which patients
can appear. Thus, these probabilities define the gaps and
differences between lines of SOFA ≤5 for each cohort
on each day.
Results
Glycemic control results for both cohorts were statisti-
cally different and are presented in [21] along with
detailed cohort and mortality data. Table 2 presents
admission and maximum SOFA scores, plus mortality
data for the whole cohort across SOFA score. No statis-
tically significant differences are seen due to low num-
bers, although raw mortality is lower in all but the very
highest maximum SOFA score group. However, these
a r et o t a lc o h o r tr e s u l t s ,w h e r et h eo r i g i n a ls t u d y[ 1 9 ]
only showed mortality differences for patients with ICU
stay three days or longer.
Figure 1 presents the percentage of patients in each
cohort with a total SOFA ≤5 for each of the first
14 days, showing organ failure resolution over time. The
clinical data are significant l yd i f f e r e n to v e rt h ef i r s t
14 days (P = 0.016). This data is fitted with an exponen-
tial curve for clarity. The clinical data are statistically
different between cohorts (P < 0.04) for the data over
the first 21, 23, 25 and 28 days. Finally, Figure 2 shows
the patient numbers per cohort by day, illustrating the
relatively low patient numbers from Day 14 onward.
Figure 3 shows the mean and mean plus one stan-
dard deviation of SOFA score for both cohorts over
the first 14 days. It is clear that there is divergence
starting at Day 2. In particular, the mean plus one
standard deviation line diverges to an increasingly
l o w e rv a l u ef o rt h eS P R I N Tcohort. This result may
Table 2 Day 1 and maximum total SOFA score for each cohort plus percent mortality and number of patients (died,
lived) by maximum SOFA score range
SPRINT Pre-SPRINT P-value
Day 1 SOFA (Mean ± SD) 5.6 ± 2.8 5.4 ± 3.0 0.20
Maximum SOFA (Mean ± SD) 6.8 ± 3.0 7.0 ± 3.2 0.76
Day of Maximum SOFA score(Median (IQR)) 1 (1, 3) 1 (1, 3) 0.99
Mortality (%) (#Died, #Lived) by maximum SOFA range
0t o4 4.4% (4, 86) 5.2% (5, 92) 0.71
5t o9 15.0% (32, 182) 15.3% (36, 199) 0.59
10 to 14 35.4% (22, 40) 40.8% (29,42) 0.79
15 to 19 75.0% (3, 1) 70.0% (7, 3) 0.79
IQR, inter-quartile range; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.
Chase et al. Critical Care 2010, 14:R154
http://ccforum.com/content/14/4/R154
Page 5 of 13explain some of the clear divergence seen as early as
t w ot of o u rd a y si nF i g u r e1 .
Figure 4 shows the daily trend of mean and mean plus
one standard deviation of the total SOFA score for both
cohorts split between survivors and non-survivors. As
expected, survivors had lower SOFA scores throughout
the time period (P < 0.01), and were similar or lower for
SPRINT (P < 0.01).
The distributions and trends by day for the individual
SOFA score components are shown in Appendix B in
Additional File 2. However, there were no visible or
clinically significant differences between the two cohorts
in the distributions for each component. SPRINT
patients did tend to have slightly lower median values
or IQR, where different, one to two days earlier than
Pre-SPRINT patients in some cases.
Examining organ-failure-free days (OFFD), SPRINT
OFFD = 1,396 out of 3,356 total possible days (41.6%)
were higher than Pre-SPRINT OFFD = 1,172 out of
3,211 (36.5%), which are significantly different
Figure 1 Percentage of patients with SOFA ≤5 over each day (to 14 days). Exponential lines are fit to the data for clarity. Clinical data are
significantly different (P ≤0.001). Modifying the lines to fit over 21, 23, 25 and 28 days yields very similar curves and significant P-values (P <
0.04) in all these ranges.
Figure 2 Patients remaining by day. At 14 days there are 67 Pre-SPRINT and 75 SPRINT patients remaining. The crossover in percentage of
cohort remaining (not shown) is between Day 3 and Day 4.
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(IOF), SPRINT = 2,681 of (Max 5 × 3,356 total possible)
or 16.0%, which was lower than Pre-SPRINT = 3,049
out of (5 × 3,211 total possible) or 19.0%, with (P <
0.0001). These results indicate that organ failures were
reduced in both numbers and time over which failures
were experienced with SPRINT. This reduction should
have an impact on mortality given the close correlation
between organ failure, SOFA score metrics and mortal-
ity in several studies.
Figure 5 shows the conditional probability (P(SOFA
≤5|c T I B≥0.5)) of SOFA ≤5g i v e nc T I B≥0.5 for each
Figure 3 Mean and Mean +1 SD lines for total SOFA score for the first 14 days for both cohorts.B yD a y s3a n d4t h e r ei sac l e a r
separation particularly for the mean + 1 SD values (P < 0.05).
Figure 4 Mean and Mean + 1SD daily trend lines for survivors and non-survivors for both cohorts. Pre-SPRINT (top) and SPRINT (bottom).
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The conditional probabilities are not statistically signifi-
cantly different until Day 14. Through Day 8 they are
effectively equivalent, which should be expected if good
control yields faster reduction of SOFA score, as this
physiological and clinical outcome should be indepen-
dent of the manner in which TGC is delivered. Differ-
ences after Day 8 could be due to several factors,
including different patient management to less acute
wards, or differences (not statistically significant in
Figure 5 Conditional probability analysis. Conditional probability of SOFA ≤5 given cTIB ≥0.5 (A) is equivalent for both cohorts, as expected,
while the cohorts differ in the percentage of patients achieving cTIB ≥0.5 (B).
Figure 6 Joint probabilities for all four combinations of SOFA score and cTIB, for both cohorts. Joint probability analysis of SOFA score
and cTIB for all four combinations given a SOFA threshold of 5 and a cTIB threshold of 0.5.
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Page 8 of 13Table 1) between cohorts, as well as evolution of differ-
ent treatment regimes such as mechanical ventilation or
steroid use. It is also clear (right panel) that far more
patients received and maintained good control under
SPRINT providing some of the difference in Figure 1.
Figure 6 shows the four joint probability cases. It is
clear from the Figure that: (1) SPRINT patients had a
higher joint probability of SOFA ≤5 with good control
as seen in Panel A, which is essentially the lines in Fig-
ure 5 (left) scaled by the lines in Figure 5 (right); (2)
Panel B shows those patients who do not improve in
SOFA score despite receiving good control, and are
effectively equivalent after six to eight days for both
cohorts, indicating those patients who simply do not
recover regardless; (3) The lines in Figure 1 are the
sum of Panels A and C, where, for the retrospective
cohort, Panel C shows that many patients can have
SOFA ≤5 despite poor control, as might be expected
clinically; (4) The remainder in Figure 1 from the
curves up to 100% (going up) are thus the sum of
Panels B and D; (5) SPRINT patients had effectively no
patients in panels C and D for poor control, per Figure
5 (right panel), after three days; (6) The Pre-SPRINT
patients (no SPRINT patients) in Panel D are thus
those who, if they had received good control, would
have moved to either Panel A or B. There are enough
patients in Panel D to cover the gap between the
cohorts in Figure 1.
These conditional and joint probabilities indicate that
while good control is not a requirement for SOFA ≤5, it
is not harmful and, further, does provide a greater likeli-
hood of reaching SOFA ≤5 for approximately 10 to 15%
of patients.
To ensure the results in Figure 5 are not due to giving
more or less insulin or nutrition compared to the rest of
the SPRINT cohort, Figure 7 shows the percent of
patients each day with SOFA ≤5w h or e c e i v e dm o r eo r
less than the cumulative median insulin or nutrition
rate for the whole cohort up to that day. It is clear that
there are no significant differences (P =0 . 2 8f o ri n s u l i n
and P = 0.13 for nutrition) in these interventions for
SOFA ≤5 patients versus the whole cohort (all SOFA
values). Hence, SOFA ≤5r e s u l t sw e r en o to b v i o u s l y
linked to receiving different insulin or nutrition than the
entire cohort.
Discussion
Only Vincent et al. [5] have examined daily SOFA score
trajectories showing its ability to capture morbidity and
mortality over time. To the authors’ knowledge, this
paper presents the first evaluation of the impact of a
clinical intervention using SOFA score and its change
over time.
The main results in Figure 1 clearly show that organ
failure resolved faster with effective TGC under the
SPRINT protocol than for a retrospective control, given
Figure 7 Impact of insulin and nutrition on SOFA scores in SPRINT. Comparison of Insulin (A) and nutrition (B) cumulative rates for SPRINT
patients with SOFA ≤5, broken into those with greater than the cumulative daily median value for the cohort, and those with less. The results
indicate that SPRINT patients with SOFA ≤5 were equally likely to receive greater or less insulin and/or nutrition than the entire cohort (all SOFA
scores).
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results show a consistent reduction in SOFA score and
organ failure for all patients, this reduction is more evi-
d e n tf o rh i g h e rp e r c e n t i l e ,m ore critically ill patients
(mean + 1SD, 83
rd percentile) with higher SOFA scores.
Figures 5 and 6 use conditional and joint probabilities
to relate TGC performance and SOFA score outcomes.
Figure 5 clearly shows that effective TGC and SOFA ≤5
are related for at least the first eight days and are not
statistically different (P > 0.06) until Day 14. This equiv-
alency reflects the hypothesis of low SOFA score being
related to effective TGC and should not depend on how
that TGC was delivered. Hence, it is primarily the differ-
ence in the percent of patients receiving effective TGC
that separates these cohorts.
Finally, Figure 6 delineates the different combinations
of TGC effectiveness and SOFA outcome. As might be
expected, Panels B and C show that some patients never
obtain SOFA ≤5 with good control, regardless of cohort,
while others achieve SOFA ≤5 despite poorer control
(cTIB < 0.5). Thus, it is panel D that indicates, in this
context, that TGC (under SPRINT) might have its great-
est benefit on the 10 to 15% of patients for whom
improved control would not be harmful and may well
define the difference in the curves of Figure 1 separating
the cohort.
There is no further specificity to the results in terms
of which specific patients or sub-groups may have dri-
ven this difference. SPRINT reported no statistically sig-
nificant difference (P > 0.35) between survivors and
non-survivors for any glycemic outcome, diabetic status,
diagnostic code, insulin infused or carbohydrate nutri-
tion, and the resultant mortality [21]. In contrast, the
retrospective cohort maintained statistically significant
associations for all glycemic outcomes except average
blood glucose and insulin infused. These results imply,
as above, that glycemic outcome was the main differ-
ence in these two cohorts and their outcomes.
Further small differences in Figure 5 after eight days
reduce the link between effective TGC of any sort and
lower SOFA score. These may have several causes, but
it should also be noted that there is a relatively large
mortality difference in patients with greater than five-
day stay in ICU between these cohorts. Other differ-
ences in cohort, patient management or unreported
changes in care may also play a role. Figure 2 reflects
some of these issues as the Pre-SPRINT cohort under-
goes far faster changes in numbers than SPRINT over
Days 4 to 10, crossing at Day 8.
Physiologically, hyperglycemia can have lasting cellular
level impact, even during subsequent euglycemia, due to
over production of superoxides [15,17], leading to
further damage and complications. Similarly, exposure
to elevated blood glucose levels over 7.0 mmol/L
resulted in significant 33 to 66% reductions in immune
response effectiveness [22,24], thus increasing the risk of
further infection and complications. These points indi-
cate that it is the long-term, cumulative quality of con-
trol that may be critical, and SPRINT provided tighter,
less variable and more consistent TGC than the
Pre-SPRINT cohort.
This study used cTIB ≥0.5 as a daily metric to assess
the consistency of tight control. This value also clearly
discriminated the SPRINT (92% of cohort met this tar-
g e ta tt h r e ed a y s )a n dP r e - S P R I N T( 3 7 % )c o h o r t s ,
clearly showing the difference in quality of control
despite similar cohort median values (6.0 mmol/L
SPRINT vs 7.2 mmol/L Retrospective). Clinically, this
metric sets a potential benchmark for assessing glycemic
performance that is directly associated, in this study,
with a clinical outcome.
With respect to limitations, a threshold of SOFA ≤5
was chosen to represent a relatively well patient
expected to survive. However, there are no clearly
defined standards for this choice, but the literature
s h o w st h a tt h i sa p p r o a c hi sc o n s e r v a t i v e .L o wn u m b e r s
for observing this phenomenon may also be a limitation,
particularly after 14 days, where Figure 2 shows only 75
and 67 patients remaining in each cohort. Note that
Christchurch Hospital does not have a high dependency
or “step down” unit, which could affect any comparison
of these patient numbers or results to some other units.
Further, potential confounders exist in any retrospec-
tive analysis as therapy approaches evolve over time. In
this case, there were no specifically implemented
changes in mechanical ventilation therapy, steroid use,
or specific sepsis campaigns. However, clinical practice
is always evolving and staff turnover has an impact as
well. Hence, these results must await repetition in a ran-
domised setting. That said, the impact of SPRINT on
nutritional inputs and carbohydrate loading is a signifi-
cant clinical difference and practice change outside the
resulting glycemic control, although it did not have a
n o t a b l ei m p a c ti nF i g u r e7w i thin the cohort. Overall,
the results presented, despite potential limitations,
should justify a randomised trial to test this approach.
It should also be noted that both the OFFD and IOF
results supported the overall result that organ failure
was reduced under SPRINT in both number and the
time experienced. However, it should be noted that IOF
could be lower if early mortality is higher as there is less
time to develop organ failures before death. However,
both cohorts reached similar maximum SOFA scores in
similar times. In addition, the equivalent lengths of stay,
combined with greater OFFD with SPRINT TGC indi-
cates that this case has not occurred.
Finally, SPRINT showed a significant improvement in
mortality for those patients staying five days or longer
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interesting. Repeating the analysis of Figure 1 for both
cohorts split into those staying five plus days and those
staying less than five days had two main results. Those
staying less than five days (median two days) had lower
SOFA scores and thus significantly higher percentages
of patients (approximately 25% absolute) with SOFA ≤5
for Days 1 to 4 compared to those who stayed five days
or longer. Thus, those staying longer had higher SOFA
scores at admission and maximum (one day), and repre-
sented a more critically ill cohort. These longer stay
patients make up the entire curve of Figure 1 from Day
5 onward. Thus, the results are effectively unchanged
from what is presented here if this division of the
cohorts is considered.
Conclusions
This study presents results from a unique analysis that
evaluates the impact of an intervention in terms of daily
organ failure status. Three main conclusions are drawn
from this analysis.
First, TGC using SPRINT had a significant effect in
resolving organ failure both faster and for a greater per-
centage of the cohort compared to a matched retrospec-
tive cohort. These results were independent of the
initial, maximum and component organ failure scores,
and independent of the time to reach the similar maxi-
mum SOFA score value, indicating the result is spread
across several factors. It also decreased total organ fail-
ure days and increased organ failure free days.
Second, the differences in SOFA score seen here can
be related to the tightness and consistency of TGC pro-
vided, as assessed by a cumulative time in band metric.
T h ec T I Bm e t r i ca n dt h et h r e s h o l du s e dp r o v i d ea n
initial benchmark result linking the quality of control to
a clinical outcome.
Third, The use of daily organ failure status and speci-
fically of the percentage of patients with resolved organ
failure provides a unique means of assessing the impact
of this (or any similar) intervention. The differences
observed reflect differences in morbidity for which the
SOFA score was designed. As such they also reflected
the mortality differences observed in these cohorts in
the original study, and did so at the same ICU length of
stay where changes in hospital and ICU mortality were
observed in the original study. Thus, the total SOFA
score used on a daily basis can provide significant
insight into the progress and efficacy of an intervention.
All of these main conclusions remain to be prospec-
tively tested. However, this analysis highlights several
key outcomes with respect to the impact of TGC and its
assessment using the SOFA score, as well as providing
some insight into potentially improved methods of
assessing similar future randomised intervention studies.
Key messages
￿ Effective, tight glycaemic control under the
SPRINT protocol to a mean of 6.0 mmol/L mitigated
organ failure faster than conventional, less tight con-
trol at a higher mean level of 7.2 mmol/L
￿ Tight glycaemic control in this study reduced total
organ failures and increased organ failure free days,
and was linked to improved SOFA score outcomes
￿ Tight glycaemic control had no impact on the
maximum SOFA scores or the day on which they
occurred indicating that its affect on organ failure
occurs after the first one to two days
￿ Daily SOFA scores provide a significant indicator
of the impact of glycaemic control on patient mor-
bidity and mortality
￿ The reduction in organ failure as measured by the
SOFA score is hypothesised as the causative factor
of the reduced mortality in the SPRINT cohort for
patients who stayed in the ICU three days or longer
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